Oriana Damas is a Gastroenterology physician. ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1120 NW 14th St
Suite 310
Miami, FL 331362107
Telephone
305-243-8644Registry record last updated 13 May 2016.
Clinical trials
- Tailored Anti-Inflammatory American Diet for Patients With Crohn's Disease
Sponsor: University of Miami
- Tailored Anti-Inflammatory (A-I) Diet for Americans With Ulcerative Colitis (UC)
Sponsor: University of Miami
- Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients
Sponsor: University of Miami
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Takeda Pharmaceuticals U.S.A., Inc.Program year20254 payments
- Janssen Scientific Affairs, LLCProgram year20251 payment
- ABBVIE INC.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
45.9%Interleukin-12 Antagonist32.4%Stelara100%Part D<11 patientsJAK inhibitor7.6%Rinvoq100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
43.2%Aminosalicylate22.7%Mesalamine60%Balsalazide Disodium41%Part D<11 patientsProton pump inhibitor8.1%Pantoprazole Sodium100%Part D<11 patients+ 2 more classes in this area
Cardiovascular
10.8%Bile Acid Sequestrant10.8%Colestipol Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2019–2026 per NIH RePORTER. The latest:
- Targeting gut inflammation through diet: a tailored American diet for patients with ulcerative colitis
University of Miami School of Medicine
FY2026$333,863R01DK140964 - Targeting gut inflammation through diet: a tailored American diet for patients with ulcerative colitis
University of Miami School of Medicine
FY2025$333,863R01DK140964 - A culturally tailored anti-inflammatory diet for Hispanic patients with ulcerative colitis
University of Miami School of Medicine
FY2024$333,863R01DK140964
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Josep M. Llovet
Institució Catalana de Recerca i Estudis Avançats
Joseph J.�Y. Sung
Nanyang Technological University
Neeraj Bhala
The Royal Melbourne Hospital
Jordi Bruix
Hospital Clínic de Barcelona
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”